Thank you for contacting Neurocrine Biosciences with your unsolicited Medical Information request regarding the recommended dosing of INGREZZA® (valbenazine) capsules.
INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.
The INGREZZA full prescribing information states that “the initial dose for INGREZZA is 40mg once daily. After one week, increase the dose to the recommended dose of 80 mg once daily. Continuation of 40 mg once daily may be considered for some patients.”
The FDA-approved prescribing information does not restrict the timing of when INGREZZA may be administered. While in previous clinical studies, valbenazine had been administered in the mornings, both morning and evening dosing is permitted in an ongoing open label (up to 72 weeks) roll-over study of valbenazine in adults with TD (patients who completed Phase 3 valbenazine trials).
This letter and the enclosed material are provided in response to your unsolicited medical information inquiry. Please feel free to contact Neurocrine Medical Information at (877) 641-3461 or firstname.lastname@example.org if you would like to request additional information.
1. INGREZZA [package insert]. Neurocrine Biosciences, Inc., San Diego, CA; 2017
2. Important Safety Information. Neurocrine Biosciences, Inc., San Diego, CA; 2017